ライフサイエンスコーパス: polymyositis

1 versity Medical Center with the diagnosis of polymyositis.

2 vels lower than those in other patients with polymyositis.

3 high muscles seen on initial MRI represented polymyositis.

4 t be distinguished histologically early from polymyositis.

5 for inclusion body myositis and unresponsive polymyositis.

6 the determining factor, and in persons with polymyositis.

7 ewly identified in a subset of patients with polymyositis.

8 n only 1/28 patients with dermatomyositis or polymyositis.

9 d necrotizing myopathy with many features of polymyositis.

10 tients are frequently misdiagnosed as having polymyositis.

11 autoimmunity in inclusion body myositis and polymyositis.

12 ermatomyositis, inclusion body myositis, and polymyositis.

13 ed therapeutic trials of dermatomyositis and polymyositis.

14 ypes in individuals with dermatomyositis and polymyositis.

15 tomyositis and, to a lesser degree, juvenile polymyositis.

16 (n = 71), systemic sclerosis 36.0% (n = 22), polymyositis 6.2% (n = 16), and adult Still's disease 0%

17 patients with dermatomyositis and some with polymyositis, a blood type 1 interferon-signature correl

18 10 children (9 with dermatomyositis, 1 with polymyositis; ages 4-15 years) twice in one day (morning

19 ponse may not be antigen driven, there is in polymyositis an overexpression of certain T-cell recepto

20 We conclude that patients with polymyositis and an excess of COX-negative muscle fibres

21 Both polymyositis and Crohn's ileocolitis responded well to c

22 (RA) (n = 80), Sjogren's syndrome (n = 30), polymyositis and dermatomyositis (n = 30), and progressi

23 omodulatory drugs are certainly effective in polymyositis and dermatomyositis despite the lack of ran

24 Various classification criteria for polymyositis and dermatomyositis have been suggested by

25 re is increasing evidence that patients with polymyositis and dermatomyositis have specific clinico-s

26 Studies in adults with polymyositis and dermatomyositis implicate interleukin-1

27 lieved that muscle weakness in patients with polymyositis and dermatomyositis is due to autoimmune an

28 unresponsive polymyositis than in responsive polymyositis and dermatomyositis patients.

29 itiation of therapy is essential, since both polymyositis and dermatomyositis respond to immunotherap

30 In the human inflammatory myopathies (polymyositis and dermatomyositis), the early, widespread

31 te diagnosis of inflammatory myopathy (i.e., polymyositis and dermatomyositis).

32 can often be found in serum of patients with polymyositis and dermatomyositis.

33 r idiopathic inflammatory myopathies such as polymyositis and dermatomyositis.

34 and includes pertinent data from adults with polymyositis and dermatomyositis.

35 l limitations and disability for adults with polymyositis and dermatomyositis.

36 A brief trial of azathioprine in polymyositis and eight studies using various treatments

37 cal IIM subclassifications: dermatomyositis, polymyositis and inclusion body myositis (IBM).

38 nflammatory muscle diseases dermatomyositis, polymyositis and inclusion body myositis are of unknown

39 and myeloid dendritic cells are abundant in polymyositis and inclusion body myositis muscle.

40 In polymyositis and inclusion body myositis, muscle fibers

41 e typically subdivided into dermatomyositis, polymyositis and inclusion body myositis.

42 In polymyositis and inclusion-body myositis, clonally expan

43 s mycophenolate mofetil is effective in both polymyositis and refractory dermatomyosits (including re

44 In polymyositis and sporadic inclusion body myositis, clona

45 igen(s) responsible for T-cell activation in polymyositis and sporadic inclusion-body myositis and th

46 -driven inflammatory cells that characterize polymyositis and sporadic inclusion-body myositis from t

47 In polymyositis and sporadic inclusion-body myositis, antig

48 h rheumatoid arthritis, 1 with lupus, 1 with polymyositis, and 6 with EUCTD).

49 ess with antigen-driven T cells identical to polymyositis, and a degenerative process in which beta-a

50 f patients with Duchenne muscular dystrophy, polymyositis, and compartment syndrome.

51 olated from samples of IBM, dermatomyositis, polymyositis, and control muscles were treated with reco

52 Inclusion body myositis, polymyositis, and dermatomyositis are three distinct cat

53 ecent therapeutic trials in dermatomyositis, polymyositis, and inclusion body myositis and suggests a

54 he inflammatory myopathies (dermatomyositis, polymyositis, and inclusion body myositis) remains obscu

55 tory myopathies, comprising dermatomyositis, polymyositis, and inclusion body myositis.

56 major and distinct subsets: dermatomyositis, polymyositis, and inclusion-body myositis.

57 whereas their prevalence in dermatomyositis, polymyositis, and other neuromuscular disorders appeared

58 divided into three groups: extreme exercise, polymyositis, and seizures.

59 Classification systems of dermatomyositis, polymyositis, and the other idiopathic inflammatory myop

60 Chronic graft-versus-host disease-related polymyositis appears to be very similar to idiopathic my

61 Dermatomyositis and polymyositis are associated with cancer, but previous na

62 cells present in inclusion body myositis and polymyositis are primarily myeloid dendritic cells.

63 Although types of malignancy seen in DM and polymyositis are similar to those in the general populat

64 Dermatomyositis and polymyositis are treatable disorders of skeletal muscle.

65 similar mechanisms appear to be involved in polymyositis associated with HTLV-I (human T cell lympho

66 transthyretin amyloidosis) can mimic that of polymyositis, but also shows that unique findings on MRI

67 rior chamber uveitis, and steroid-responsive polymyositis confirmed by electrophysiologic studies.

68 n the past 2 years, with particular focus on polymyositis, dermatomyositis and inclusion body myositi

69 eterogeneous group of diseases that includes polymyositis, dermatomyositis, and inclusion body myosit

70 yositis syndromes (the most common forms are polymyositis, dermatomyositis, and inclusion body myosit

71 and 2B, Miyoshi myopathy, nemaline myopathy, polymyositis, dermatomyositis, and inclusion body myosit

72 the most common inflammatory myopathies are polymyositis, dermatomyositis, and inclusion body myosit

73 ed in patients with inclusion-body myositis, polymyositis, dermatomyositis, and neurogenic muscle atr

74 pus erythematosus, Wegener's granulomatosis, polymyositis, dermatomyositis, polyarteritis nodosa, or

75 ly associated with a subset of patients with polymyositis/dermatomyositis (PM/DM) complicated by inte

76 to determine whether sera from patients with polymyositis/dermatomyositis (PM/DM) with or without int

77 se who had 45-55-kd bands, all patients with polymyositis/dermatomyositis (PM/DM), and a random selec

78 erythematosus, 121 with scleroderma, 86 with polymyositis/dermatomyositis [PM/DM]) and 248 Italian pa

79 cytoplasmic antibody-associated vasculitis, polymyositis/dermatomyositis, and primary Sjogren's synd

80 I, 1.10-1.27) and specific prior autoimmune (polymyositis/dermatomyositis, systemic sclerosis, autoim

81 nti-RHA was not observed in any patient with polymyositis/dermatomyositis, systemic sclerosis, rheuma

82 tingly, similar to what is observed in human polymyositis/dermatomyositis, the mice developed a stron

83 ated 10 patients with histologically typical polymyositis except for an excess of muscle fibres with

84 ermatomyositis, inclusion body myositis, and polymyositis gained from large-scale microarray gene exp

85 cle biopsy in 2 patients in the unresponsive polymyositis group demonstrated histological features of

86 All patients with dermatomyositis and polymyositis (> or =15 years old) were identified by dis

87 patients with adult-onset dermatomyositis or polymyositis had a baseline assessment a median of 30 mo

88 137 of the 914 cases of polymyositis had cancer, which developed after diagnosis

89 patients with IIM, in particular those with polymyositis, had no strong disease associations with HL

90 Although inclusion body myositis and polymyositis have been characterized as cytotoxic CD8(+)

91 d cancer, which developed after diagnosis of polymyositis in 95.

92 bellar degeneration (PCD) in HL and dermato/ polymyositis in both HL and NHL, other PNSs are uncommon

93 losing spondylitis, psoriatic arthritis, and polymyositis, in 36 patients.

94 ) infection, studies into a primate model of polymyositis induced by HTLV-I may be particularly infor

95 Polymyositis is an uncommon disorder that can be misdiag

96 A breed-specific polymyositis is frequently observed in the Hungarian Viz

97 The relation with polymyositis is much weaker, if at all present.

98 rt here the first known case of inflammatory polymyositis leading to rhabdomyolysis in a male patient

99 previously healthy man presented with acute polymyositis leading to rhabdomyolysis.

100 ases, such as SLE, rheumatoid arthritis, and polymyositis may occur de novo or exacerbate.

101 c inflammatory myopathy (dermatomyositis and polymyositis) may have in certain instances extramuscula

102 y, certain intractable childhood epilepsies, polymyositis, multiple sclerosis, optic neuritis, and th

103 lation alterations were observed in juvenile polymyositis (n = 5) and other IIMs (n = 9).

104 farction (n = 10), myonecrosis due either to polymyositis or crush injuries (n = 12), and septic shoc

105 A total of 37 patients with polymyositis or dermatomyositis were randomized (19 to c

106 milies with other siblings or relatives with polymyositis or dermatomyositis, and 2 families with inc

107 significant adverse effects in patients with polymyositis or dermatomyositis.

108 occur in approximately 25% of patients with polymyositis or dermatomyositis.

109 d systemic lupus erythematosus (SLE); 17 had polymyositis or dermatomyositis; 16 had scleroderma; eig

110 and in a similar percentage of patients with polymyositis or systemic sclerosis.

111 agnosed with either inclusion body myositis, polymyositis, or dermatomyositis.

112 ) age-matched patients with dermatomyositis, polymyositis, or necrotizing myopathy, and 0/20 (0%) age

113 itis, Sjogren's syndrome, dermatomyositis or polymyositis, or scleroderma were of borderline statisti

114 e of onset was 9 years older than a group of polymyositis patients with normal COX staining of muscle

115 lt or juvenile IIM, comprising patients with polymyositis (PM) (n=114), dermatomyositis (DM) (n=102),

116 Adults with refractory polymyositis (PM) and adults and children with refractor

117 of UK Caucasian patients have confirmed that polymyositis (PM) and dermatomyositis (DM) are not genet

118 markers in IBM compared with normal control, polymyositis (PM) and non-inflammatory dystrophy sample

119 vo in patients with dermatomyositis (DM) and polymyositis (PM) in order to evaluate the role of mitoc

120 Polymyositis (PM) is an autoimmune muscle disease charac

121 diffuse interstitial lung disease and either polymyositis (PM) or dermatomyositis (DM).

122 c controls, two dermatomyositis (DM) and two polymyositis (PM) patients was reverse transcribed and r

123 es, but occurred more often in patients with polymyositis (PM) than in those with dermatomyositis (DM

124 e episodes (MELAS), dermatomyositis (DM) and polymyositis (PM) using pairwise statistical comparison

125 the pathogenesis of the diverse entities of polymyositis (PM), dermatomyositis (DM), and inclusion b

126 echanisms were analysed in biopsies of sIBM, polymyositis (PM), dermatomyositis (DM), dystrophic and

127 from 44 patients with dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM), myasth

128 scle disorders include Dermatomyositis (DM), Polymyositis (PM), Necrotizing Myositis (NM), and sporad

129 52), in the muscle biopsies of patients with polymyositis (PM), PM associated with human immunodefici

130 e dermatomyositis (DM), compared to juvenile polymyositis (PM), was assessed in 298 juvenile IIM pati

131 ctively from consecutive adult patients with polymyositis (PM; n = 134), dermatomyositis (n = 129), o

132 ients were carrying a diagnosis of infantile polymyositis prior to immunostaining studies.

133 patients with established dermatomyositis or polymyositis receiving chronic medical therapies who are

134 In both dermatomyositis and polymyositis, risk of malignant disease was highest at t

135 Sera from some patients with polymyositis-scleoderma overlap syndrome (PM-SCL) recogn

136 the 100 kDa antigenic component of the human polymyositis scleroderma (PMSCL) autoantigen, is a 3'-->

137 100, an autoantibody target in patients with polymyositis, scleroderma, or polymyositis-scleroderma o

138 The anti-polymyositis-scleroderma autoantibody is associated with

139 lated the rat (r) homologue of the human (h) polymyositis-scleroderma autoantigen (PM-Scl), which has

140 9 but not with human Ubc5, MyoD, Id3, or the polymyositis-scleroderma autoantigen.

141 te domain that is found also in Homo sapiens polymyositis-scleroderma overlap syndrome 100 kDa autoan

142 y autoimmune sera of patients suffering from polymyositis-scleroderma overlap syndrome.

143 eroderma autoantibody is associated with the polymyositis-scleroderma overlap syndrome.

144 patients with polymyositis, scleroderma, or polymyositis-scleroderma overlap syndrome.

145 The polymyositis/scleroderma autoantigen gene was overexpres

146 ividual cancer sites for dermatomyositis and polymyositis separately, using national cancer rates by

147 A polymyositis syndrome has been described as a rare compl

148 in inclusion body myositis and unresponsive polymyositis than in responsive polymyositis and dermato

149 leroderma; Sjogren Syndrome; dermatomyositis/polymyositis; unspecified/mixed CTD; other inflammatory

150 ted, the association of Crohn's disease with polymyositis varies in its complexity and severity.

151 Polymyositis was associated with a raised risk of non-Ho

152 markers led to the suspicion of inflammatory polymyositis, which was confirmed by electromyography an

153 also modestly increased among patients with polymyositis, with an excess for some cancers.

154 dence of autoimmunity in dermatomyositis and polymyositis, with strong correlations between particula